1
|
Fry S, Chokephaibulkit K, Pallem S, Henry O, Pu Y, Akawung A, Kim JH, Yanni E, Tullio AN, Aurpibul L, Lee CMF, Ceballos A, Zaman K, Abadía de Regalado I, Ahmed K, Arias Fernandez DA, Taher SW, Caccavo J, Coutinho CM, D’Andrea Nores U, De León T, D’Silva EC, De Bernardi M, Dieser P, Falaschi A, Flores Acosta CDC, Gentile A, Teo IH, Kotze S, López-Medina E, Luca R, Lucion MF, Mantaring JBIIIV, Marín B, Moelo M, Mussi-Pinhata MM, Pinto J, Puthanakit T, Reyes O, Roa MF, Rodriguez Brieschke MT, Rodriguez CE, Rodriguez Niño JN, Schwarzbold AV, Sierra Garcia A, Sivapatham L, Soon R, Tinoco JC, Velásquez Penagos JA, Dos Santos G. Incidence of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Illness in Infants in Low- and Middle-Income Regions During the Coronavirus Disease 2019 Pandemic. Open Forum Infect Dis 2023; 10:ofad553. [PMID: 38088983 PMCID: PMC10715683 DOI: 10.1093/ofid/ofad553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Indexed: 12/30/2023] Open
Abstract
Background Incidence data of respiratory syncytial virus-associated lower respiratory tract illness (RSV-LRTI) are sparse in low- and middle-income countries (LMICs). We estimated RSV-LRTI incidence rates (IRs) in infants in LMICs using World Health Organization case definitions. Methods This prospective cohort study, conducted in 10 LMICs from May 2019 to October 2021 (largely overlapping with the coronavirus disease 2019 [COVID-19] pandemic), followed infants born to women with low-risk pregnancies for 1 year from birth using active and passive surveillance to detect potential LRTIs, and quantitative reverse-transcription polymerase chain reaction on nasal swabs to detect RSV. Results Among 2094 infants, 32 (1.5%) experienced an RSV-LRTI (8 during their first 6 months of life, 24 thereafter). Seventeen (0.8%) infants had severe RSV-LRTI and 168 (8.0%) had all-cause LRTI. IRs (95% confidence intervals [CIs]) of first RSV-LRTI episode were 1.0 (.3-2.3), 0.8 (.3-1.5), and 1.6 (1.1-2.2) per 100 person-years for infants aged 0-2, 0-5, and 0-11 months, respectively. IRs (95% CIs) of the first all-cause LRTI episode were 10.7 (8.1-14.0), 11.7 (9.6-14.0), and 8.7 (7.5-10.2) per 100 person-years, respectively. IRs varied by country (RSV-LRTI: 0.0-8.3, all-cause LRTI: 0.0-49.6 per 100 person-years for 0- to 11-month-olds). Conclusions RSV-LRTI IRs in infants in this study were relatively low, likely due to reduced viral circulation caused by COVID-19-related nonpharmaceutical interventions. Clinical Trials Registration NCT03614676.
Collapse
Affiliation(s)
- Samantha Fry
- Department of Paediatrics and Child Health, Family Centre for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa
| | - Kulkanya Chokephaibulkit
- Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | | | | | | | | | | | | | | - Linda Aurpibul
- Research Institute for Health Science, Chiang Mai University, Chiang Mai, Thailand
| | | | - Ana Ceballos
- Instituto Médico Río Cuarto, Río Cuarto, Córdoba, Argentina
| | - Khalequ Zaman
- International Centre for Diarrhoeal Disease Research (icddr, b), Dhaka, Bangladesh
| | | | - Khatija Ahmed
- Setshaba Research Centre, Soshanguve, South Africa
- Faculty of Health Sciences, Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa
| | | | | | - Juliana Caccavo
- Donación Francisco Santojanni Hospital, Buenos Aires, Argentina
| | - Conrado Milani Coutinho
- Department of Gynecology and Obstetrics, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil
| | | | - Tirza De León
- Maternity Hospital José Domingo De Obaldia, San Pablo Viejo, Panama
| | | | | | - Pablo Dieser
- Instituto Médico Río Cuarto, Río Cuarto, Córdoba, Argentina
| | - Andrea Falaschi
- Dr Ramon Carrillo Hospital, Mendoza, Argentina
- Dr Diego Paroissien Hospital, Mendoza, Argentina
| | | | - Angela Gentile
- Epidemiology Department, Hospital de Niños Dr Ricardo Gutiérrez, Buenos Aires, Argentina
| | | | - Sheena Kotze
- Synexus Stanza Clinical Research Centre, Pretoria, South Africa
| | - Eduardo López-Medina
- Centro de Estudios en Infectología Pediátrica, Department of Pediatrics, Universidad del Valle, Valle del Cauca, Colombia
- Clinica Imbanaco, Grupo Quironsalud, Cali, Colombia
| | - Ruben Luca
- Hospital F. F. Santojanni C1407, Buenos Aires, Argentina
| | - Maria Florencia Lucion
- Epidemiology Department, Hospital de Niños Dr Ricardo Gutiérrez, Buenos Aires, Argentina
| | - Jacinto Blas III V Mantaring
- Department of Clinical Epidemiology, University of the Philippines, Philippine General Hospital, Manila, Philippines
| | | | | | | | - Jorge Pinto
- Department of Pediatrics, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - Thanyawee Puthanakit
- Department of Pediatrics and Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Osvaldo Reyes
- Santo Tomás Hospital, Panama City, Panama
- Centro de Vacunación Internacional S.A., La Chorrera, Panama
- Member of the Sistema Nacional de Investigadores (SNI), Panama City, Panama
| | - Maria Fernanda Roa
- Department of Pediatrics, University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | | | - Camilo Enrique Rodriguez
- Department of Gynecology and Obstetrics, University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia
- School of Medicine, University of the Andes, Bogotá, Colombia
| | | | - Alexandre Vargas Schwarzbold
- Hospital Universitário de Santa Maria, Centro de Pesquisa Clínica, Universidade Federal de Santa Maria, Santa Maria, Brazil
| | - Alexandra Sierra Garcia
- Centro de Estudios en Infectología Pediátrica, Department of Pediatrics, Universidad del Valle, Valle del Cauca, Colombia
- Clinica Imbanaco, Grupo Quironsalud, Cali, Colombia
| | - Lavitha Sivapatham
- Department of Obstetrics and Gynecology, Ampang Hospital, Ampang, Malaysia
| | - Ruey Soon
- Department of Obstetrics and Gynecology, Sabah Women's and Children's Hospital, Kota Kinabalu, Malaysia
| | | | | | | |
Collapse
|
2
|
Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sánchez MG, Banooni P, Gardener GJ, Rasero JLB, Pardilla MBE, Langley JM, Di Leo CM, Botelho-Nevers E, Buttery J, Laurichesse H, Madhi SA, García AM, Stanley T, Barjat T, Griffith R, Castrejón-Alba MM, de Heusch M, Dieussaert I, Hercor M, Lese P, Qian H, Tullio AN, Henry O. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis 2023; 228:299-310. [PMID: 36722147 PMCID: PMC10420396 DOI: 10.1093/infdis/jiad024] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 01/23/2023] [Accepted: 01/27/2023] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND In a phase 1/2 study, a maternal respiratory syncytial virus vaccine candidate (RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV-specific humoral immune responses in non-pregnant women. METHODS In this phase 2 observer-blind, placebo-controlled, randomized clinical trial (NCT04126213), the safety of RSVPreF3 (60 or 120 µg), administered during late second or third trimester, was evaluated in 213 18- to 40-year-old healthy pregnant women through 6 months postdelivery and their offspring through infancy; immunogenicity was evaluated through day 43 postdelivery and day 181 postbirth, respectively. RESULTS RSVPreF3 was well tolerated. No pregnancy-related or neonatal adverse events of special interest were considered vaccine/placebo related. In the 60 and 120 µg RSVPreF3 groups: (1) neutralizing antibody (nAb) titers in mothers increased 12.7- and 14.9-fold against RSV-A and 10.6- and 13.2-fold against RSV-B, respectively, 1 month postvaccination and remained 8.9-10.0-fold over prevaccination at day 43 postdelivery; (2) nAb titers were consistently higher compared to placebo recipients; (3) placental transfer ratios for anti-RSVPreF3 antibodies at birth were 1.62 and 1.90, respectively, and (4) nAb levels in infants were highest at birth and declined through day 181 postbirth. CONCLUSIONS RSVPreF3 maternal vaccination had an acceptable safety risk profile and induced robust RSV-specific immune responses with successful antibody transfer to their newborns. CLINICAL TRIALS REGISTRATION NCT04126213.
Collapse
Affiliation(s)
| | - Osvaldo Reyes
- International Vaccination Centre, National Network of Researchers of Panama, Panama, Panama
| | | | - Anu Kantele
- Meilahti Vaccine Research Centre, Inflammation Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | | | | | | | - Glenn J Gardener
- Mater Research Institute, University of Queensland, South Brisbane, Australia
| | | | | | - Joanne M Langley
- Canadian Center for Vaccinology, IWK Health Centre, Nova Scotia Health Authority–Dalhousie University, Halifax, Nova Scotia, Canada
| | | | - Elisabeth Botelho-Nevers
- Infectious and Tropical Diseases Department, CIC 1408 INSERM, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
| | - Jim Buttery
- Infection and Immunity Department, Monash Children's Hospital, Melbourne, Victoria, Australia
| | - Helene Laurichesse
- Centre Hospitalier Universitaire Clermont-Ferrand, Clermont Ferrand, France
| | - Shabir A Madhi
- South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Adrián Martín García
- Department of Obstetrics and Gynecology, Hospital Universitario de Burgos, Burgos, Spain
| | - Thorsten Stanley
- University of Otago and Wellington Hospital, Wellington, New Zealand
| | - Tiphaine Barjat
- Department of Gynecology and Obstetrics, CIC 1408 INSERM, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Riley M, Lambrelli D, Graham S, Henry O, Sutherland A, Schmidt A, Sawalhi-Leckenby N, Donaldson R, Stoszek SK. Adverse infant outcomes following low-risk pregnancies in England: a retrospective cohort study. BMC Pregnancy Childbirth 2023; 23:330. [PMID: 37161382 PMCID: PMC10170847 DOI: 10.1186/s12884-023-05598-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Accepted: 04/11/2023] [Indexed: 05/11/2023] Open
Abstract
BACKGROUND There are limited data describing adverse infant outcomes in infants born to women with a low risk of complications during pregnancy, such as those who may be enrolled in maternal immunization trials. This retrospective study estimated incidence proportions of infant outcomes in different cohorts of liveborn infants in England between 2005 and 2017. METHODS The incidence proportions of 10 infant outcomes were calculated for liveborn infants from pregnancies represented in the Clinical Practice Research Datalink (CPRD) Mother-Baby Link (MBL) and linkage to Hospital Episode Statistics (HES). Three infant cohorts were designed: (1) the all pregnancies infants cohort (N = 185,119), (2) the all pregnancies with a gestational age (GA) ≥ 24 weeks infants cohort (N = 183,869), and (3) the low-risk pregnancies infants cohort (LR infants cohort, N = 121,871), which included pregnancies with a GA ≥ 24 weeks and no diagnosis of predefined high-risk medical conditions until 24 weeks GA. RESULTS The most common adverse infant outcome in the three infant cohorts was macrosomia (e.g., 1,085.9/10,000 live births in the LR infants cohort), followed by minor congenital anomalies (e.g., 800.6/10,000 in the LR infants cohort), very low/low birth weight (e.g., 400.6/10,000 in the LR infants cohort), and major congenital anomalies (e.g., 270.4/10,000 in the LR infants cohort). The incidence proportions for early-onset sepsis, very low/low birth weight, and minor and major congenital anomalies were lower in the LR infants than in the other cohorts (non-overlapping confidence intervals [CIs]). The incidence proportions of neonatal death, infant death, late-onset sepsis, macrosomia, small for GA, and large for GA were similar between cohorts (overlapping CIs). CONCLUSIONS This study generated background rates of adverse infant outcomes from liveborn infants of all and low-risk pregnancies represented in the CPRD Pregnancy Register MBL and linkage to HES. The results indicate lower incidence proportions of several adverse infant outcomes in infants from low-risk pregnancies compared to all pregnancies, illustrating the importance of considering maternal risk factors. These background rates may facilitate the interpretation of safety data from maternal immunization trials and of pharmacovigilance data from maternal vaccines. They may also be of interest for other interventions studied in pregnant women.
Collapse
Affiliation(s)
- Megan Riley
- GSK, 14200 Shady Grove Rd, Rockville, MD 20850, USA.
| | | | - Sophie Graham
- Evidera, 201 Talgarth Rd, Hammersmith, W6 8BJ, London, UK
| | - Ouzama Henry
- GSK, 14200 Shady Grove Rd, Rockville, MD 20850, USA
| | - Andrea Sutherland
- GSK, 14200 Shady Grove Rd, Rockville, MD 20850, USA
- Present affiliation: Moderna, Cambridge, MA, USA
| | - Alexander Schmidt
- GSK, 14200 Shady Grove Rd, Rockville, MD 20850, USA
- Present affiliation: Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA
| | | | | | - Sonia K Stoszek
- GSK, 14200 Shady Grove Rd, Rockville, MD 20850, USA
- Present affiliation: Moderna, Cambridge, MA, USA
| |
Collapse
|
4
|
Riley M, Lambrelli D, Graham S, Henry O, Sutherland A, Schmidt A, Sawalhi-Leckenby N, Donaldson R, Stoszek SK. Facilitating safety evaluation in maternal immunization trials: a retrospective cohort study to assess pregnancy outcomes and events of interest in low-risk pregnancies in England. BMC Pregnancy Childbirth 2022; 22:461. [PMID: 35650569 PMCID: PMC9157029 DOI: 10.1186/s12884-022-04769-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 05/09/2022] [Indexed: 11/10/2022] Open
Abstract
Background Maternal characteristics like medical history and health-related risk factors can influence the incidence of pregnancy outcomes and pregnancy-related events of interest (EIs). Data on the incidence of these endpoints in low-risk pregnant women are needed for appropriate external safety comparisons in maternal immunization trials. To address this need, this study estimated the incidence proportions of pregnancy outcomes and pregnancy-related EIs in different pregnancy cohorts (including low-risk pregnancies) in England, contained in the Clinical Practice Research Datalink (CPRD) Pregnancy Register linked to Hospital Episode Statistics (HES) between 2005 and 2017. Methods The incidence proportions of 7 pregnancy outcomes and 15 EIs were calculated for: (1) all pregnancies (AP) represented in the CPRD Pregnancy Register linked to HES (AP cohort; N = 298 155), (2) all pregnancies with a gestational age (GA) ≥ 24 weeks (AP24+ cohort; N = 208 328), and (3) low-risk pregnancies (LR cohort; N = 137 932) with a GA ≥ 24 weeks and no diagnosis of predefined high-risk medical conditions until 24 weeks GA. Results Miscarriage was the most common adverse pregnancy outcome in the AP cohort (1 379.5 per 10 000 pregnancies) but could not be assessed in the other cohorts because these only included pregnancies with a GA ≥ 24 weeks, and miscarriages with GA ≥ 24 weeks were reclassified as stillbirths. Preterm delivery (< 37 weeks GA) was the most common adverse pregnancy outcome in the AP24+ and LR cohorts (742.9 and 680.0 per 10 000 pregnancies, respectively). Focusing on the cohorts with a GA ≥ 24 weeks, the most common pregnancy-related EIs in the AP24+ and LR cohorts were fetal/perinatal distress or asphyxia (1 824.3 and 1 833.0 per 10 000 pregnancies), vaginal/intrauterine hemorrhage (799.2 and 729.0 per 10 000 pregnancies), and labor protraction/arrest disorders (752.4 and 774.5 per 10 000 pregnancies). Conclusions This study generated incidence proportions of pregnancy outcomes and pregnancy-related EIs from the CPRD for different pregnancy cohorts, including low-risk pregnancies. The reported incidence proportions of pregnancy outcomes and pregnancy-related EIs are largely consistent with external estimates. These results may facilitate the interpretation of safety data from maternal immunization trials and the safety monitoring of maternal vaccines. They may also be of interest for any intervention studied in populations of pregnant women. Supplementary Information The online version contains supplementary material available at 10.1186/s12884-022-04769-x.
Collapse
Affiliation(s)
- Megan Riley
- GSK, 14200 Shady Grove Rd, Rockville, MD, 20850, Washington, USA.
| | | | - Sophie Graham
- Evidera, 201 Talgarth Rd, Hammersmith, London, W6 8BJ, UK
| | - Ouzama Henry
- GSK, 14200 Shady Grove Rd, Rockville, MD, 20850, Washington, USA
| | - Andrea Sutherland
- GSK, 14200 Shady Grove Rd, Rockville, MD, 20850, Washington, USA.,Moderna, Cambridge, MA, USA
| | - Alexander Schmidt
- GSK, 14200 Shady Grove Rd, Rockville, MD, 20850, Washington, USA.,Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA
| | | | | | - Sonia K Stoszek
- GSK, 14200 Shady Grove Rd, Rockville, MD, 20850, Washington, USA.,Moderna, Cambridge, MA, USA
| |
Collapse
|
5
|
Assouline A, Schernberg A, Huet de Froberville H, Dinh P, Biggs E, Henry O, Cadot P, Lievre C, Weirich L, Delanian S, Pradat PF. Radiothérapie des glandes salivaires pour le traitement de la sialorrhée au cours de la sclérose latérale amyotrophique et la maladie de Parkinson : analyse de 281 cas. Cancer Radiother 2021. [DOI: 10.1016/j.canrad.2021.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Mouchet-Mages S, Alezrah C, Allag-Morris S, Blachère P, Bouvier JC, Chollier M, Colson MH, Cordier B, Da Costa J, De Fréminville H, Delarue JM, Dufresne K, Dusacq E, Frémy D, Giron O, Goetz F, Henry O, Le Bodic C, Lemitre S, Letto N, Maquigneau A, Miele C, Moncany AH, Plancade O, Sadowski I, Truffaut J, Lacambre M. [Towards better management for sexual offenders: Presentation and conclusions of a public hearing concerning prevention, assessment, and care]. Encephale 2021; 47:495-498. [PMID: 33422285 DOI: 10.1016/j.encep.2020.06.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Accepted: 06/29/2020] [Indexed: 11/25/2022]
Abstract
In France, since the law of June 17, 1998, sexual offenders may be convicted to ambulatory mandatory care, articulated with the justice. Twenty years after the implementation of this law, while social and technological developments have redefined certain aspects of delinquency, reference documents and practice guidelines remain to be updated. This is why the professionals of the main structures and associations dealing with perpetrators of sexual violence organized a public hearing under the sponsorship of the French Federation of Resource Centers for Sexual Violence Perpetrators (FFCRIAVS) according to the methodology and with the accompaniment of the High Authority of Health. This article presents the global methodology of the public hearing "Sexual Offenders: Prevention, Evaluation and Care" which was conducted on June 14 and 15, 2018. Thirty-three experts replied to27 questions and presented their conclusions to an Audition Committee and an audience of 200 persons representative of the civil and professional society. After a public debate, the hearing committee prepared a report in which they proposed propositions in order to better care for sexual offenders.
Collapse
Affiliation(s)
- S Mouchet-Mages
- CRIAVS Rhône-Alpes, centre hospitalier Le Vinatier, 95, boulevard Pinel, 69678 Lyon, France.
| | - C Alezrah
- CREI-ORS Occitanie, 31000 Toulouse, France.
| | | | - P Blachère
- Groupe de travail médico-légal de l'AIUS, Marseille, France.
| | - J-C Bouvier
- Application des peines du TGI de Paris, 75000 Paris, France.
| | - M Chollier
- CRIR-AVS PACA, département études interdisciplinaires, Manchester Metropolitan University, Assistance publique-Hôpitaux de Marseille, 13005 Marseille , France.
| | - M-H Colson
- CISIH, hôpital de Sainte Marguerite de Marseille, 13009 Marseille, France.
| | - B Cordier
- Hôpital Foch de Suresnes, 92150 Suresnes, France.
| | - J Da Costa
- UFR médecine Toulouse-Purpan, université Paul Sabatier, 31000 Toulouse, France.
| | | | - J-M Delarue
- Lieux de privation de liberté (2008-2014), Paris, France.
| | - K Dufresne
- Service Pénitentiaire d'Insertion et de Probation (SPIP) du Pas-de-Calais, 62041 Arras, France.
| | - E Dusacq
- Unité sanitaire maison d'arrêt Villeneuve-lès-Maguelone, CRIAVS-LR, CHU de Montpellier, 34750 Montpellier, France.
| | - D Frémy
- Unité du psychotraumatisme (centre hospitalier Novillars), CRIAVS mineurs de Franche-Comté, Paris, France.
| | - O Giron
- SMPR, CHU de Nantes, Nantes, France.
| | - F Goetz
- Délégation générale à l'administration pénitentiaire et à la réinsertion du royaume du Maroc en qualité de conseiller résident de jumelage pour l'Union européenne, Paris, France.
| | - O Henry
- UFR médecine Toulouse - Purpan, université Paul Sabatier, 31000 Toulouse, France.
| | - C Le Bodic
- EPSM Morbihan, pôle Saint Avé-Ploërmel, 56890 Saint-Avé, France.
| | - S Lemitre
- Centre de soin des traumatismes et violences, Paris, France.
| | - N Letto
- CRIAVS Île-de-France, 75000 Paris, France.
| | - A Maquigneau
- CRIR-AVS PACA, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France.
| | - C Miele
- CRIAVS Auvergne, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France.
| | - A-H Moncany
- CRIAVS Midi-Pyrénées, centre hospitalier Marchant, 31000 Toulouse, France.
| | - O Plancade
- CRIAVS Rhône-Alpes délégation de Lyon, SMDPL, centre hospitalier Le Vinatier, 69678 Bron, France.
| | - I Sadowski
- Coordination de l'aide aux victimes, Victimes, Paris, France.
| | - J Truffaut
- Université Paris Descartes, trésorière adjointe de l'ARTAAS, Paris, France.
| | - M Lacambre
- Fédération française des centres ressources pour les intervenants auprès d'auteurs de violences sexuelles (FFCRIAVS), Paris, France.
| |
Collapse
|
7
|
Schwarz TF, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N, Nguyen TLA, Gao FF, Qian H, Tullio AN, Dieussaert I, Picciolato M, Henry O. Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in non-pregnant women. J Infect Dis 2021; 225:2067-2076. [PMID: 34146100 PMCID: PMC9200160 DOI: 10.1093/infdis/jiab317] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 06/29/2021] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Respiratory syncytial virus (RSV) causes respiratory tract infections, which may require hospitalization especially in early infancy. Transplacental transfer of RSV antibodies could confer protection to infants in their first months of life. METHODS In this first-in-human, placebo-controlled study, 502 healthy non-pregnant women were randomized 1:1:1:1 to receive a single dose of unadjuvanted vaccine containing 30/60/120 µg of RSV fusion (F) protein stabilized in the prefusion conformation (RSVPreF3), or placebo. RESULTS Solicited local adverse events (AEs) were more frequently reported in the RSVPreF3 groups (4-53.2%) vs placebo (0-15.9%); most were mild/moderate. Unsolicited AEs were comparably reported among groups. Three serious AEs were reported; none was vaccination-related. Compared with pre-vaccination values, anti-RSV A neutralizing antibody geometric mean titers and anti-RSVPreF3 immunoglobulin G geometric mean concentrations increased 8-14-fold and 12-21-fold at day (D)8 and persisted 5-6-fold and 6-8-fold higher until D91 in the RSVPreF3 groups vs 1-fold in placebo. Comparisons at D8 and D31 showed that the higher dose levels were significantly more immunogenic than the lowest one. CONCLUSIONS The RSVPreF3 vaccine was well tolerated and immunogenic. The 60 and 120 µg dose levels were selected for further investigation in pregnant women.
Collapse
Affiliation(s)
- Tino F Schwarz
- Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany
| | | | | | | | - Peter Csonka
- Centre for Child Health Research, Tampere University, Tampere, Finland
| | | | | | | | - Hui Qian
- GSK, Rockville, MD, United States
| | | | | | | | | |
Collapse
|
8
|
Habib MA, Prymula R, Carryn S, Esposito S, Henry O, Ravault S, Usonis V, Wysocki J, Gillard P, Povey M. Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. Vaccine 2021; 39:3445-3454. [PMID: 33736915 DOI: 10.1016/j.vaccine.2021.02.074] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 02/15/2021] [Accepted: 02/28/2021] [Indexed: 12/26/2022]
Abstract
BACKGROUND Varicella vaccination confers high and long-lasting protection against chickenpox and induces robust immune responses, but an absolute correlate of protection (CoP) against varicella has not been established. This study models the relationship between varicella humoral response and protection against varicella. METHODS This was a post-hoc analysis of data from a Phase IIIb, multicenter, randomized trial (NCT00226499) conducted in ten varicella-endemic European countries. Healthy children aged 12-22 months were randomized 3:3:1 to receive one dose of measles-mumps-rubella and one dose of varicella vaccine (one-dose group) or two doses of measles-mumps-rubella-varicella vaccine (two-dose group) or two doses of measles-mumps-rubella vaccine (control group) six weeks apart. The study remained observer-blind until completion, except in countries with obligatory additional immunizations. The objective was to correlate varicella-specific antibody concentrations with protection against varicella and probability of varicella breakthrough, using Cox proportional hazards and Dunning and accelerated failure time statistical models. The analysis was guided by the Prentice framework to explore a CoP against varicella. RESULTS The trial included 5803 participants, 5289 in the efficacy (2266: one-dose group, 2279: two-dose group and 744: control group) and 5235 (2248, 2245 and 742 in the same groups) in the immunogenicity cohort. The trial ended in 2016 with a median follow-up time of 9.8 years. Six weeks after vaccination with one- or two-dose varicella-containing vaccine, more than 93.0% of vaccinees were seropositive for varicella-specific antibodies. Estimated vaccine efficacy correlated positively with antibody concentrations. The fourth Prentice CoP criterion was not met, due to predicted positive vaccine efficacy in seronegative participants. Further modelling showed decreased probability of moderate to severe varicella breakthrough with increasing varicella-specific antibody concentrations (ten-year probability <0.1 for antibody concentrations ≥2-fold above the seropositivity cut-off). CONCLUSIONS Varicella-specific antibody concentrations are a good predictor of protection, given their inverse correlation with varicella occurrence. CLINICAL TRIAL NCT00226499.
Collapse
Affiliation(s)
| | - Roman Prymula
- Charles University, Faculty of Medicine, Department of Social Medicine, Simkova street 870, 500 03 Hradec Kralove, Czechia.
| | | | - Susanna Esposito
- Pediatric Clinic Pietro Barilla Children's Hospital, Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy.
| | - Ouzama Henry
- GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA.
| | | | - Vytautas Usonis
- Clinic of Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. Čiurlionio g. 21/27, 03101 Vilnius, Lithuania.
| | - Jacek Wysocki
- Department of Preventive Medicine, University of Medical Sciences, ul. Święcickiego 6, 60-781 Poznań, Poland.
| | | | | |
Collapse
|
9
|
Leroux-Roels G, Bebia Z, Maes C, Aerssens A, De Boever F, Grassano L, Buffi G, Margarit I, Karsten A, Cho S, Slobod K, Corsaro B, Henry O. Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial. Clin Infect Dis 2021; 70:2570-2579. [PMID: 31394574 PMCID: PMC7286364 DOI: 10.1093/cid/ciz737] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 08/09/2019] [Indexed: 12/23/2022] Open
Abstract
Background Maternal immunization against group B streptococcus (GBS) could protect infants from invasive GBS disease. Additional doses in subsequent pregnancies may be needed. We evaluated the safety and immunogenicity of a second dose of an investigational trivalent CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III), administered to nonpregnant women 4–6 years postdose 1. Methods Healthy women either previously vaccinated with 1 dose of trivalent GBS vaccine 4–6 years before enrollment (n = 53) or never GBS vaccinated (n = 27) received a single trivalent GBS vaccine injection. Adverse events (AEs) were recorded. Serotype-specific (Ia/Ib/III) anti-GBS antibodies were measured by multiplex immunoassay prevaccination and 30/60 days postvaccination. Results AEs were reported with similar rates after a first or second dose; none were serious. Of previously GBS-vaccinated women, 92%–98% had anti-GBS concentrations that exceeded an arbitrary threshold (8 µg/mL) for each serotype 60 days postdose 2 vs 36%–56% postdose 1 in previously non–GBS-vaccinated women. Of previously GBS-vaccinated women with undetectable baseline (predose 1) anti-GBS levels, 90%–98% reached this threshold postdose 2. For each serotype, anti-GBS geometric mean concentrations (GMCs) 30/60 days postdose 2 in previously GBS-vaccinated women were ≥200-fold higher than baseline GMCs. Among women with undetectable baseline anti-GBS levels, postdose 2 GMCs in previously GBS-vaccinated women exceeded postdose 1 GMCs in previously non–GBS-vaccinated women (≥7-fold). Conclusions A second trivalent GBS vaccine dose administered 4–6 years postdose 1 was immunogenic with a favorable safety profile. Women with undetectable preexisting anti-GBS concentrations may benefit from a sufficiently spaced second vaccine dose. Clinical Trials Registration NCT02690181
Collapse
Affiliation(s)
- Geert Leroux-Roels
- Center for Vaccinology, Ghent University and Ghent University Hospital, Belgium
| | | | - Cathy Maes
- Center for Vaccinology, Ghent University and Ghent University Hospital, Belgium
| | - Annelies Aerssens
- Center for Vaccinology, Ghent University and Ghent University Hospital, Belgium
| | - Fien De Boever
- Center for Vaccinology, Ghent University and Ghent University Hospital, Belgium
| | | | | | | | | | - Stephen Cho
- Novartis, Cambridge, Massachusetts.,GSK, Cambridge, Massachusetts
| | - Karen Slobod
- Novartis, Cambridge, Massachusetts.,GSK, Cambridge, Massachusetts
| | | | | |
Collapse
|
10
|
Schwarz T, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N, Nguyen TLA, Gao FF, Soni J, Tullio AN, Dieussaert I, Picciolato M, Henry O. 1239. Different Dose Levels of a Respiratory Syncytial Virus Maternal Vaccine Candidate (RSVPreF3) Administered to Non-pregnant Women in a Randomized Clinical Trial Are Immunogenic and Well Tolerated. Open Forum Infect Dis 2020. [PMCID: PMC7776676 DOI: 10.1093/ofid/ofaa439.1424] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Background Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in childhood. Maternal immunization could help to protect infants from RSV-associated infections in their first months of life. We evaluated the safety, reactogenicity and immunogenicity of the RSV maternal (RSVPreF3) vaccine candidate in non-pregnant women, at different dose levels. Methods In this phase I/II, observer-blind, multicenter study (NCT03674177), healthy non-pregnant women aged 18–45 years were randomized (1:1:1:1) and received 1 dose of either 30, 60 or 120 µg of RSVPreF3 vaccine (30/60/120 RSVPreF3 group) or placebo. Solicited adverse events (AEs) (until day 7 [D7] post-vaccination), unsolicited AEs (until D30 post-vaccination), hematological and biochemical laboratory abnormalities (at D8 and D31 post-vaccination) were recorded. Serious AEs (SAEs) were collected until D181 and immune responses until D91 post-vaccination. Exploratory analysis was performed at D31 to compare immunogenicity of different dose levels. Results 502 women were included in the exposed set. The most frequently reported solicited AEs were pain and headache (Fig 1). Grade 3 solicited AEs were infrequently reported. 180 women experienced unsolicited AEs; 19 reported grade 3 unsolicited AEs, among which 1 was vaccination-related (60 RSVPreF3). 3 SAEs were reported (1 in 120 RSVPreF3; 2 in placebo); none was related to vaccination. No clinically significant changes in laboratory parameters occurred. Geometric mean titers of anti-RSV A neutralizing antibody (≥ 8-fold at D8 and ≥ 5-fold until D91 vs baseline) and geometric mean concentrations of anti-RSVPreF3 IgG antibody (≥ 12-fold at D8 and ≥ 6-fold until D91 vs baseline) were boosted in all RSVPreF3 groups (Fig 2, 3). The 60 and 120 µg dose levels of RSVPreF3 were significantly more immunogenic than the 30 µg one. Figure 1. Solicited adverse events until day 7 post-vaccination ![]()
Figure 2. GMTs of anti-RSV A neutralizing antibody (ED60) until day 91 post-vaccination ![]()
Figure 3. GMCs of RSVPreF3 IgG antibody (EU/mL) until day 91 post-vaccination ![]()
Conclusion All RSVPreF3 vaccine dose levels were well tolerated and no safety concerns identified. All 3 dose levels were immunogenic, with higher immune response induced by the 60 and 120 µg dose levels than the 30 µg one. These data support the further investigation of the 60 and 120 µg RSVPreF3 dose levels in pregnant women. Funding GlaxoSmithKline Biologicals SA Acknowledgment N Bulik/Q Deraedt (Modis c/o GSK) provided writing/editorial support Disclosures Tino Schwarz, PhD, GSK group of companies (Scientific Research Study Investigator, Speaker’s Bureau) Christine Grigat, MD, GSK group of companies (Scientific Research Study Investigator) Dan Apter, MD, PhD, GSK group of companies (Research Grant or Support) Peter Csonka, MD, PhD, GSK group of companies (Scientific Research Study Investigator) Thi Lien-Anh Nguyen, PhD, GSK group of companies (Employee, Shareholder) Feng F. Gao, PhD, GSK group of companies (Employee) Jyoti Soni, MA, GSK group of companies (Employee) Antonella Nadia Tullio, Dr., GSK group of companies (Employee) Ilse Dieussaert, IR, GSK group of companies (Employee, Shareholder) Marta Picciolato, PharmD, MSc, GSK group of companies (Employee) Ouzama Henry, MD, GSK group of companies (Employee, Shareholder)
Collapse
Affiliation(s)
- Tino Schwarz
- Klinikum Wuerzburg Mitte, Standort Juliusspital, Wuerzburg, Baden-Wurttemberg, Germany
| | - Casey Johnson
- Johnson County Clin-Trials, Lenexa, KS, United States, Lenexa, Kansas
| | - Christine Grigat
- Clinical Research Hamburg, Hamburg, Germany, Hamburg, Hamburg, Germany
| | - Dan Apter
- VL-Medi, Helsinki, Finland, Helsinki, Uusimaa, Finland
| | - Peter Csonka
- Centre for Child Health Research, Tampere University, Tampere, Finland, Tampere, Pirkanmaa, Finland
| | - Niklas Lindblad
- University of Turku, Turku, Finland, Turku, Varsinais-Suomi, Finland
| | | | - Feng F Gao
- GSK, Rockville, MD, United States, Rockville, Maryland
| | - Jyoti Soni
- GSK, Bangalore, India, Bangalore, Karnataka, India
| | | | | | | | - Ouzama Henry
- GSK, Rockville, MD, United States, Rockville, Maryland
| |
Collapse
|
11
|
Madhi SA, Izu A, Kwatra G, Jones S, Dangor Z, Wadula J, Moultrie A, Adam Y, Pu W, Henry O, Briner C, Cutland CL. Association of Group B streptococcus serum serotype-specific anti-capsular IgG concentration and risk reduction for invasive Group B streptococcus disease in South African infants: an observational birth-cohort, matched case-control study. Clin Infect Dis 2020; 73:e1170-e1180. [PMID: 33341870 DOI: 10.1093/cid/ciaa1873] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Licensure of a Group B streptococcus (GBS) polysaccharide-protein conjugate vaccine for protecting infants against invasive GBS disease (IGbsD) will likely need to be based on demonstrating vaccine safety in pregnant women, and benchmarking immunogenicity against a serological threshold associated with risk reduction of IGbsD. We investigated the association between naturally-derived GBS serotype-Ia and III IgG and risk reduction of IGbsD in infants' ≤90 days of age. METHODS In a matched case-control study (ClinicalTrials.gov NCT02215226), IGbsD cases were identified from a cohort of 38,233 mother-newborn dyads. Mothers colonized vaginally with serotype-Ia or III at birth, and their healthy infants were eligible as matched controls. GBS serotype-specific anti-capsular IgG was measured on maternal and cord blood/infant sera by multiplex Luminex assay; and the IgG threshold associated with 90% risk reduction of IGbsD derived by estimating absolute disease risk. RESULTS In infants born ≥34 weeks gestational age, cord-blood IgG geometric mean concentrations (GMC) were lower in cases than controls for serotype-Ia (0.05 vs. 0.50µg/ml; p=0.004) and III (0.20 vs. 0.38µg/ml; p=0.078). Cord-blood IgG concentration ≥1.04 and ≥1.53µg/ml were associated with 90% risk reduction of serotype-Ia and III IGbsD, respectively. The maternal sera IgG threshold associated with 90% risk reduction was ≥2.31 and ≥3.41µg/ml for serotype-Ia and III, respectively. CONCLUSIONS The threshold associated with a reduced risk for serotype-Ia and III IGbsD identified on infant sera supports the case for licensure of a GBS polysaccharide-protein conjugate vaccine based on immunogenicity evaluation benchmarked against the defined thresholds.
Collapse
Affiliation(s)
- Shabir A Madhi
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa
| | - Alane Izu
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa
| | - Gaurav Kwatra
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa
| | - Stephanie Jones
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa
| | - Ziyaad Dangor
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa.,Department of Paediatrics, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Jeanette Wadula
- National Health Laboratory Services, Department of Anatomical Pathology, School of Pathology, University of the Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa
| | - Andrew Moultrie
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa
| | - Yasmin Adam
- Department of Obstetrics and Gynecology, Chris Hani-Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | | | | | - Carmen Briner
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa
| | - Clare L Cutland
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), University of the Witwatersrand, Faculty of Health Science Johannesburg, South Africa.,Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa
| |
Collapse
|
12
|
Swamy GK, Metz TD, Edwards KM, Soper DE, Beigi RH, Campbell JD, Grassano L, Buffi G, Dreisbach A, Margarit I, Karsten A, Henry O, Lattanzi M, Bebia Z. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. Vaccine 2020; 38:6930-6940. [PMID: 32883555 DOI: 10.1016/j.vaccine.2020.08.056] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 08/18/2020] [Accepted: 08/20/2020] [Indexed: 01/31/2023]
Abstract
BACKGROUND This study evaluated the safety and immunogenicity of an investigational trivalent group B streptococcus (GBS) vaccine in US pregnant women, transplacental serotype-specific antibody transfer and persistence in infants, and serotype-specific antibodies in breast milk. METHODS This randomized, observer-blind, placebo-controlled trial administered one dose of trivalent GBS vaccine (n = 49) or placebo (n = 26) to healthy pregnant 18-40-year-old women at 240/7-346/7 weeks' gestation. Women were enrolled from March 2014 to August 2015. Safety follow-up continued through postpartum day 180. Primary immunogenicity objectives were to evaluate serotype Ia/Ib/III-specific immunoglobulin G (IgG) levels in sera from women on day 1 (pre-vaccination), day 31, delivery and postpartum days 42 and 90, and from infants at birth (cord blood), days 42 and 90. Antibody transfer ratios (cord blood/maternal sera at delivery) and serotype-specific secretory immunoglobulin A (sIgA) and IgG in breast milk after delivery and on postpartum days 42 and 90 were evaluated. The planned sample size was not based on statistical assumptions for this descriptive study. RESULTS Baseline characteristics were similar between groups. Serious adverse events were reported for 16% of GBS-vaccinated women and 15% of their infants, and 15% of placebo recipients and 12% of their infants; none were fatal or deemed vaccine-related. Serotype-specific IgG geometric mean concentrations (GMCs) were 13-23-fold higher in vaccine vs placebo recipients on day 31 and persisted until postpartum day 90. Median antibody concentrations were substantially higher in women with detectable pre-vaccination antibody concentrations. Antibody transfer ratios in the vaccine group were 0.62-0.82. Infant IgG GMCs and breast milk sIgA GMCs were higher in the vaccine vs the placebo group at all timepoints. CONCLUSIONS Maternal immunization with the trivalent GBS vaccine in US women had a favorable safety profile, elicited antibodies that were transplacentally transferred and persisted in infants for a minimum of 3 months. CLINICAL TRIAL REGISTRATION Clinicaltrials.gov, NCT02046148.
Collapse
Affiliation(s)
- Geeta K Swamy
- Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA.
| | - Torri D Metz
- Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, CO, USA.
| | - Kathryn M Edwards
- Vanderbilt Vaccine Research Program, Vanderbilt University, Nashville, TN, USA.
| | - David E Soper
- Medical University of South Carolina, Charleston, SC, USA.
| | - Richard H Beigi
- UPMC Magee-Women's Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
| | - James D Campbell
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Beran J, Leroux-Roels G, Van Damme P, de Hoon J, Vandermeulen C, Al-Ibrahim M, Johnson C, Peterson J, Baker S, Seidl C, Dreisbach A, Karsten A, Corsaro B, Henry O, Lattanzi M, Bebia Z. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. Vaccine 2020; 38:3227-3234. [DOI: 10.1016/j.vaccine.2020.02.085] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2019] [Revised: 02/20/2020] [Accepted: 02/29/2020] [Indexed: 01/10/2023]
|
14
|
Delaby N, Martin S, Barateau A, Henry O, Perichon N, De Crevoisier R, Chajon E, Castelli J, Lafond C. Implementation of an optimization method for parotid gland sparing during inverse planning for head and neck cancer radiotherapy. Cancer Radiother 2020; 24:28-37. [PMID: 32007370 DOI: 10.1016/j.canrad.2019.09.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 09/09/2019] [Accepted: 09/10/2019] [Indexed: 12/28/2022]
Abstract
PURPOSE To guide parotid gland (PG) sparing at the dose planning step, a specific model based on overlap between PTV and organ at risk (Moore et al.) was developed and evaluated for VMAT in head-and-neck (H&N) cancer radiotherapy. MATERIALS AND METHODS One hundred and sixty patients treated for locally advanced H&N cancer were included. A model optimization was first performed (20 patients) before a model evaluation (110 patients). Thirty cases were planned with and without the model to quantify the PG dose sparing. The inter-operator variability was evaluated on one case, planned by 12 operators with and without the model. The endpoints were PG mean dose (Dmean), PTV homogeneity and number of monitor units (MU). RESULTS The PG Dmean predicted by the model was reached in 89% of cases. Using the model significantly reduced the PG Dmean: -6.1±4.3Gy. Plans with the model showed lower PTV dose homogeneity and more MUs (+10.5% on average). For the inter-operator variability, PG dose volume histograms without the optimized model were significantly different compared to those with the model; the Dmean standard deviation for the ipsilateral PG decreased from 2.2Gy to 1.2Gy. For the contralateral PG, this value decreased from 2.9Gy to 0.8Gy. CONCLUSION During the H&N inverse planning, the optimized model guides to the lowest PG achievable mean dose, allowing a significant PG mean dose reduction of -6.1Gy. Integrating this method at the treatment-planning step significantly reduced the inter-patient and inter-operator variabilities.
Collapse
Affiliation(s)
- N Delaby
- Centre Eugène Marquis, Unité de Physique Médicale, rue de La Bataille Flandres Dunkerque, CS 44229, 35042 Rennes Cedex, France.
| | - S Martin
- Centre Eugène Marquis, Département de Radiothérapie, rue de La Bataille Flandres Dunkerque, CS 44229, 35042 Rennes Cedex, France
| | - A Barateau
- Université Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France
| | - O Henry
- Centre Eugène Marquis, Unité de Physique Médicale, rue de La Bataille Flandres Dunkerque, CS 44229, 35042 Rennes Cedex, France
| | - N Perichon
- Centre Eugène Marquis, Unité de Physique Médicale, rue de La Bataille Flandres Dunkerque, CS 44229, 35042 Rennes Cedex, France
| | - R De Crevoisier
- Université Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France
| | - E Chajon
- Centre Eugène Marquis, Département de Radiothérapie, rue de La Bataille Flandres Dunkerque, CS 44229, 35042 Rennes Cedex, France
| | - J Castelli
- Université Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France
| | - C Lafond
- Université Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France
| |
Collapse
|
15
|
Jouyaux F, Henry O, Biron E, Coste F, Danhier S, Benchalal M, Gesnouin P, Getain M, P. Le Dorze GL, Prince CL, Lecoeur P, Leleu C, Llagostera C, Vigouroux FL, Martin E, Martineau S, Palisson J, Perrot S, Prodhomme T, Vela A, Collet S. 22- A multi-center study of breast irradiation techniques. Phys Med 2019. [DOI: 10.1016/j.ejmp.2019.09.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
16
|
Monnet P, Zehou O, Khemri M, Hirsch G, Rakotonarivo L, Jankovic M, Thomas E, Fromentin I, Haulon S, Henry O, Bouillanne O, Motamed G, Schwald-Adam N, David JP, Mezière A, Picou Y, Schonheit C, Jannic A, Gautier MS, Lestang P, Plaquet JL, Charpentier C, Ostojic A, Wolkenstein P, Duong TA. Prise en charge des tumeurs cutanées par télédermatologie : quel parcours de soins dans une filière gériatrique ? Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Le Pechoux C, Botticella A, Levy A, Henry O, Chabert I, Caramella C. MS07.06 Hot Topics in SBRT - Biopsy, Central Lesions, Radiologic Evaluation. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. J Pediatric Infect Dis Soc 2019; 9:194-201. [PMID: 30849175 PMCID: PMC7192400 DOI: 10.1093/jpids/piz010] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 01/18/2019] [Accepted: 02/28/2019] [Indexed: 11/21/2022]
Abstract
BACKGROUND MMR II (M-M-R II [Merck & Co, Inc.]) is currently the only measles, mumps, and rubella (MMR) vaccine licensed in the United States. A second MMR vaccine would mitigate the potential risk of vaccine supply shortage or delay. In this study, we assessed the immunogenicity and safety of another MMR vaccine (MMR-RIT [Priorix, GlaxoSmithKline]) compared with those of the MMR II in 12- to 15-month-old children who received it as a first dose. METHODS In this phase III, observer-blinded, noninferiority, lot-to-lot consistency clinical trial (ClinicalTrials.gov identifier NCT01702428), 5003 healthy children were randomly assigned to receive 1 dose of MMR-RIT (1 of 3 production lots) or MMR II along with other age-recommended routine vaccines. We evaluated the immunogenicity of all vaccines in terms of antibody concentrations (by using an enzyme-linked immunosorbent assay or electrochemiluminescence assay) and/or seroresponse rates 43 days after vaccination. We also assessed the reactogenicity and safety of the vaccines. RESULTS Immunoresponses after vaccination with MMR-RIT were robust and noninferior to those after vaccination with the MMR II. Immunogenicity of the 3 production lots of MMR-RIT was consistent; more than 97% of the children had a seroresponse to MMR components. The coadministered vaccines elicited similar immunoresponses in the MMR-RIT and MMR II groups. Both MMR vaccines resulted in comparable reactogenicity profiles, and no safety concerns were detected. CONCLUSIONS If licensed, the MMR-RIT could provide a valid option for the prevention of measles, mumps, and rubella in children in the United States and would reduce potential risks of a vaccine shortage.
Collapse
Affiliation(s)
- Nicola P Klein
- Kaiser Permanente Vaccine Study Center, Oakland, California,Correspondence: N. P. Klein, Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612 ()
| | | | | | - Mercedes Macias Parra
- Department of Infectious Diseases, Instituto Nacional de Pediatría, Mexico City, Mexico
| | - Javier Diez-Domingo
- Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica (FISABIO-Public Health), Valencia, Spain
| | - Anitta Ahonen
- Vaccine Research Center, University of Tampere, Finland
| | | | | | - Leonard Weiner
- Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York
| | - Gary S Marshall
- Department of Pediatrics, University of Louisville School of Medicine, Kentucky
| | | | - Kwabena O Sarpong
- Sealy Center for Vaccine Development, University of Texas, Galveston
| | | | - John A Fling
- Department of Pediatrics, University of North Texas Health Science Centre, Fort Worth
| | - David Speicher
- Pediatric Pulmonary Division, Rainbow Babies and Children’s Hospital, Cleveland, Ohio
| | - Maribel Campos
- Puerto Rico Clinical and Translational Research Consortium, San Juan
| | - Iona Munjal
- Department of Pediatrics, Children’s Hospital at Montefiore, Bronx, New York
| | - Christopher Peltier
- Department of Pediatrics, University of Cincinnati College of Medicine and Pediatric Associates of Mt. Carmel, Inc, Ohio
| | - Timo Vesikari
- Vaccine Research Center, University of Tampere, Finland
| | | | | | | | | | | |
Collapse
|
19
|
Povey M, Henry O, Riise Bergsaker MA, Chlibek R, Esposito S, Flodmark CE, Gothefors L, Man S, Silfverdal SA, Štefkovičová M, Usonis V, Wysocki J, Gillard P, Prymula R. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infect Dis 2019; 19:287-297. [PMID: 30765242 DOI: 10.1016/s1473-3099(18)30716-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 09/14/2018] [Accepted: 11/09/2018] [Indexed: 12/14/2022]
Abstract
BACKGROUND The duration of protection provided by varicella vaccines is unclear. We assessed the 10-year vaccine efficacy of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV), one live attenuated varicella vaccine (V) dose given after one measles-mumps-rubella vaccine (MMR) dose (MMR + V), versus two MMR doses (control vaccine) for the prevention of confirmed varicella. METHODS This was a phase 3b follow-up of an observer-blinded, randomised, controlled trial. In phase a, children aged 12-22 months (at first vaccination) from Czech Republic (Czechia), Greece, Italy, Lithuania, Norway, Poland, Romania, Russia, Slovakia, and Sweden were randomly assigned by computer-generated randomisation list (3:3:1) to receive two doses of MMRV, one dose of MMR and one dose of varicella vaccine, or two doses of MMR, 42 days apart. Varicella cases were confirmed by detection of viral DNA, or epidemiological link and clinical assessment, by an independent data monitoring committee; disease severity was based on a modified Vázquez scale. Hazard ratios for MMRV and MMR + V versus MMR estimated in the per-protocol cohort using a Cox proportional hazards regression model were used to calculate vaccine efficacy and 95% CI. Serious adverse events were recorded throughout the study in all vaccinated children. Study objectives were secondary and descriptive. The trial is registered at ClinicalTrials.gov, number NCT00226499. FINDINGS Between Sept 1, 2005, and May 10, 2006, 5803 children (mean age 14·2 months, SD 2·5) were vaccinated. The per-protocol cohort included 2279 children from the MMRV group, 2266 from the MMR + V group, and 744 from the MMR group. From baseline to a median follow-up of 9·8 years, 76 (3%) children in the MMRV group, 469 (21%) in the MMR + V group, and 352 (47%) in the MMR group had varicella. Vaccine efficacy against all varicella was 95·4% (95% CI 94·0-96·4) for MMRV and 67·2% (62·3-71·5) for MMR + V; vaccine efficacy against moderate or severe varicella was 99·1% (97·9-99·6) for MMRV and 89·5% (86·1-92·1) for MMR + V. During phase b, serious adverse events were reported by 290 (15%) of 1961 children in the MMRV group, 317 (16%) of 1978 in the MMR + V group, and 93 (15%) of 641 in the MMR group. There were no treatment-related deaths. INTERPRETATION The 10-years vaccine efficacy observed, suggests that a two-dose schedule of varicella vaccine provided optimum long-term protection for the prevention of varicella by offering individual protection against all severities of disease and leading to a potential reduction in transmission, as observed in the US experience with universal mass vaccination. FUNDING GlaxoSmithKline Biologicals.
Collapse
Affiliation(s)
| | | | - Marianne A Riise Bergsaker
- Division of Health Services, Department of Global Health, Norwegian Institute of Public Health, Oslo, Norway
| | - Roman Chlibek
- University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic
| | - Susanna Esposito
- Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy
| | | | - Leif Gothefors
- The Public Health Agency of Sweden and Department of Clinical Sciences/Pediatrics, Umeå University, Umeå, Sweden
| | - Sorin Man
- 3rd Pediatric Department, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | | | - Mária Štefkovičová
- Faculty of Health Care, Alexander Dubček University of Trenčín, Trenčín, Slovakia
| | - Vytautas Usonis
- Clinic of Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Jacek Wysocki
- Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland
| | | | - Roman Prymula
- University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic; Charles University, Faculty of Medicine in Hradec Kralove, Department of Social Medicine, Hradec Kralove, Czech Republic
| |
Collapse
|
20
|
Faust SN, Le Roy M, Pancharoen C, Weber MAR, Cathie K, Behre U, Bernatoniene J, Snape MD, Helm K, Medina Pech CE, Henry O, Baccarini C, Povey M, Gillard P. Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. BMC Pediatr 2019; 19:50. [PMID: 30732648 PMCID: PMC6366055 DOI: 10.1186/s12887-019-1425-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Accepted: 01/31/2019] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was immunologically non-inferior to the HSA-containing vaccine and well-tolerated in toddlers; low-grade fever was numerically higher in children receiving the vaccine without HSA, but the study lacked power to conclude on this difference. METHODS In this phase III, double-blind, multi-center study, healthy 12-23-month-olds were randomized (1:1) to receive two doses of the varicella vaccine without (Var-HSA group) or with HSA (Var + HSA group) at days 0 and 42. The primary objective compared safety of the vaccines in terms of incidence of fever > 39.0 °C in the 15-day period post-first vaccination. The objective was considered met if the upper limit of the 95% confidence interval for the between-group difference in the incidence of fever > 39.0 °C was ≤5% (Var-HSA group minus Var + HSA group). Safety, reactogenicity and immune responses were evaluated. RESULTS Six hundred fifteen children in the Var-HSA group and 616 in the Var + HSA group received ≥1 vaccination. Fever > 39.0 °C was reported in 3.9 and 5.2% of participants in the Var-HSA and Var + HSA groups, with a between-group difference of - 1.29 (95% confidence interval: - 3.72-1.08); therefore, the primary objective was achieved. Fever rates post-each dose and the incidence of solicited local and general adverse events (AEs) were comparable between groups. Unsolicited AEs were reported for 43.9 and 36.5% of children in the Var-HSA group and 45.8 and 36.0% of children in the Var + HSA group, during 43 days post-dose 1 and 2, respectively. Serious AEs occurred in 2.1% (group Var-HSA) and 2.4% (group Var + HSA) of children, throughout the study. In a sub-cohort of 364 children, all had anti-varicella-zoster virus antibody concentrations ≥50 mIU/mL post-dose 2; comparable geometric mean concentrations were observed between the groups. CONCLUSIONS The varicella vaccine formulated without HSA did not induce higher rates of fever during the 15 day-post-vaccination period, as compared with the original HSA-containing vaccine. The two vaccines displayed similar safety and immunogenicity profiles in toddlers. TRIAL REGISTRATION NCT02570126 , registered on 5 October 2015 (www.clinicaltrials.gov).
Collapse
Affiliation(s)
- Saul N Faust
- NIHR Southampton Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, UK.
| | | | - Chitsanu Pancharoen
- Department of Pediatrics and Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand
| | - Miguel Angel Rodriguez Weber
- Instituto Nacional de Pediatria, Insurgentes Sur 3700C Col. Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | - Katrina Cathie
- NIHR Southampton Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, UK
| | - Ulrich Behre
- Private Practice, Hauptstrasse 240, 77694, Kehl, Germany
| | - Jolanta Bernatoniene
- Pediatric Infectious Disease Department, Education Centre Level 6, University Hospitals Bristol NHS Foundation Trust, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8AE, UK
| | - Matthew D Snape
- Oxford Vaccine Group, Department of Pediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Headington, Oxford, OX3 9DU, UK
| | - Klaus Helm
- Private practice, Paulinenstrasse 71a, 32756, Detmold, Germany
| | - Carlos Eduardo Medina Pech
- Medical Care and Research SA de CV, Calle 32 No. 217 Col. Garcia Gineres, 97070, Mérida, Yucatán, Mexico
| | - Ouzama Henry
- GSK, 14200 Shady Grove Rd, Rockville, MD, 20850, USA
| | - Carmen Baccarini
- GSK at the time of study conduct, 160 North Gulph Road, King of Prussia, PA, 19406, USA
| | | | | |
Collapse
|
21
|
Lafond C, Laffont S, Bellec J, Henry O, Perdrieux M, Jouyaux F, Perichon N, Delaby N, Hervé C. 64 Management of the medical physics students in internship: Feedback of Centre Eugène Marquis (Regional Cancer Center of Rennes/France). Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.09.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
22
|
Hirsch G, Thomas E, Fromentin I, Haulon S, Henry O, Bouillanne O, Motamed G, Schwald-Adam N, David JP, Hua C, Zehou O, Thion P, Chosidow O, Wolkenstein P, Duong TA. TELDERM : télé-expertise en dermatologie : évolution sur 21 mois dans un établissement gériatrique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.388] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Delaby N, Bouvier J, Sorel S, Arab-Ceschia F, Henry O, Bellec J, Lafond C. 5 Peripheral doses in stereotactic brain treatments: Comparison Versa HD®/CyberKnife® M6™. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.09.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
24
|
Barateau A, Perichon N, Castelli J, Schick U, Henry O, Chajon E, Simon A, Lafond C, De Crevoisier R. A density assignment method for dose monitoring in head-and-neck radiotherapy. Strahlenther Onkol 2018; 195:175-185. [PMID: 30302507 DOI: 10.1007/s00066-018-1379-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 09/26/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND AND PURPOSE During head-and-neck (H&N) radiotherapy, the parotid glands (PGs) may be overdosed; thus, a tool is required to monitor the delivered dose. This study aimed to assess the dose accuracy of a patient-specific density assignment method (DAM) for dose calculation to monitor the dose to PGs during treatment. PATIENTS AND METHODS Forty patients with H&N cancer received an intensity modulated radiation therapy (IMRT), among whom 15 had weekly CTs. Dose distributions were calculated either on the CTs (CTref), on one-class CTs (1C-CT, water), or on three-class CTs (3C-CT, water-air-bone). The inter- and intra-patient DAM uncertainties were evaluated by the difference between doses calculated on CTref and 1C-CTs or 3C-CTs. PG mean dose (Dmean) and spinal cord maximum dose (D2%) were considered. The cumulated dose to the PGs was estimated by the mean Dmean of the weekly CTs. RESULTS The mean (maximum) inter-patient DAM dose uncertainties for the PGs (in cGy) were 23 (75) using 1C-CTs and 12 (50) using 3C-CTs (p ≤ 0.001). For the spinal cord, these uncertainties were 118 (245) and 15 (67; p ≤ 0.001). The mean (maximum) DAM dose uncertainty between cumulated doses calculated on CTs and 3C-CTs was 7 cGy (45 cGy) for the PGs. Considering the difference between the planned and cumulated doses, 53% of the ipsilateral and 80% of the contralateral PGs were overdosed by +3.6 Gy (up to 8.2 Gy) and +1.9 Gy (up to 5.2 Gy), respectively. CONCLUSION The uncertainty of the three-class DAM appears to be clinically non-significant (<0.5 Gy) compared with the PG overdose (up to 8.2 Gy). This DAM could therefore be used to monitor PG doses and trigger replanning.
Collapse
Affiliation(s)
- A Barateau
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France.
| | - N Perichon
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France
| | - J Castelli
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France
| | - U Schick
- Radiotherapy Department, CHU Brest, 29000, Brest, France
| | - O Henry
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France
| | - E Chajon
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France
| | - A Simon
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France
| | - C Lafond
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France
| | - R De Crevoisier
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000, Rennes, France
| |
Collapse
|
25
|
Jouyaux F, Henry O, Biron E, Coste F, Danhier S, Delaby N, Gesnouin P, Le Dorze P, Le Prince C, Lecoeur P, Leleu C, Llagostera C, Martin É, Martineau S, Palisson J, Vela A, Collet S. Radiothérapie externe du sein et des aires ganglionnaires : étude dosimétrique multicentrique. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Henry O, Brzostek J, Czajka H, Leviniene G, Reshetko O, Gasparini R, Pazdiora P, Plesca D, Desole MG, Kevalas R, Gabutti G, Povey M, Innis B. Corrigendum to "One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life" [Vaccine 36 (2018) 381-387]. Vaccine 2018; 36:6894. [PMID: 30244871 DOI: 10.1016/j.vaccine.2018.09.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Ouzama Henry
- Vaccine Discovery and Development, GSK, Philadelphia, United States.
| | | | - Hanna Czajka
- Infectious Diseases Outpatient Clinic, The St. Luis Provincial Specialist Children's Hospital, Cracow, Poland.
| | - Giedra Leviniene
- Pediatric Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania.
| | - Olga Reshetko
- Pharmacology, Saratov Medical University, Saratov, Russia.
| | | | - Petr Pazdiora
- Department of Epidemiology, Medical Faculty Pilsen of Charles University, Czech Republic.
| | - Doina Plesca
- Pediatrics, University of Medicine and Pharmacy, Bucharest, Romania.
| | | | - Rimantas Kevalas
- Pediatric Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania.
| | - Giovanni Gabutti
- Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
| | | | - Bruce Innis
- Vaccine Discovery and Development, GSK, Philadelphia, United States.
| |
Collapse
|
27
|
Castelli J, Simon A, Rigaud B, Chajon E, Thariat J, Benezery K, Vauleon E, Jegoux F, Henry O, Lafond C, de Crevoisier R. Adaptive radiotherapy in head and neck cancer is required to avoid tumor underdose. Acta Oncol 2018; 57:1267-1270. [PMID: 29706107 DOI: 10.1080/0284186x.2018.1468086] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- J. Castelli
- Radiotherapy Department, Centre Eugene Marquis, Rennes, France
- Université de Rennes 1, LTSI, Campus de Beaulieu, Rennes, France
- INSERM, U1099, Campus de Beaulieu, Rennes, France
| | - A. Simon
- Université de Rennes 1, LTSI, Campus de Beaulieu, Rennes, France
- INSERM, U1099, Campus de Beaulieu, Rennes, France
| | - B. Rigaud
- Université de Rennes 1, LTSI, Campus de Beaulieu, Rennes, France
- INSERM, U1099, Campus de Beaulieu, Rennes, France
| | - E. Chajon
- Radiotherapy Department, Centre Eugene Marquis, Rennes, France
| | - J. Thariat
- Radiotherapy Department, Centre François Baclesse, Caen, France
| | - K. Benezery
- Radiotherapy Department, Centre Antoine Lacassagne, Nice, France
| | - E. Vauleon
- Department of Oncology, Centre Eugene Marquis, Rennes, France
| | - F. Jegoux
- Head and Neck Department, CHU Rennes, Rennes, France
| | - O. Henry
- Radiotherapy Department, Centre Eugene Marquis, Rennes, France
| | - C. Lafond
- Radiotherapy Department, Centre Eugene Marquis, Rennes, France
- Université de Rennes 1, LTSI, Campus de Beaulieu, Rennes, France
- INSERM, U1099, Campus de Beaulieu, Rennes, France
| | - R. de Crevoisier
- Radiotherapy Department, Centre Eugene Marquis, Rennes, France
- Université de Rennes 1, LTSI, Campus de Beaulieu, Rennes, France
- INSERM, U1099, Campus de Beaulieu, Rennes, France
| |
Collapse
|
28
|
Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study. Hum Vaccin Immunother 2018; 14:2624-2631. [PMID: 29902133 PMCID: PMC6314414 DOI: 10.1080/21645515.2018.1489186] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The introduction of vaccination programs against measles, mumps, and rubella (MMR) led to significant global reduction in morbidity and mortality from these diseases. The currently recommended MMR vaccination schedule in the United States of America comprises 2 vaccine doses typically administered at 12–15 months and 4–6 years, respectively. Considering recent outbreaks in the USA, catch-up vaccination with an additional dose of MMR vaccine could contribute to outbreak control and community protection. This phase III, observer-blind, randomized controlled trial (NCT02058563) assessed the immunogenicity and safety of a dose of the MMR-RIT vaccine (Priorix, GSK) compared to MMR II vaccine (control; M-M-R II, Merck&Co Inc.) in ≥7-year-olds who had received ≥1 previous dose of MMR vaccine. We assessed anti-measles, anti-mumps, and anti-rubella antibody geometric mean concentrations (GMCs; primary endpoint) and seroresponse rates (SRRs) at day 42 post-vaccination. Solicited, unsolicited, and serious adverse events (AEs) were recorded. The according-to-protocol cohort for immunogenicity included 869 participants (MMR-RIT: N = 433; MMR II: N = 436). We observed anti-measles, anti-mumps, and anti-rubella antibody GMCs of 1790.2 mIU/mL, 113.5 EU/mL, and 76.1 IU/mL, respectively, and SRRs of 98.8%, 98.4%, and 99.5%, respectively, after a dose of MMR-RIT; non-inferiority compared to MMR II was demonstrated. Both vaccines showed comparable reactogenicity profiles; the most common solicited AEs were injection site redness and pain, and fever (MMR-RIT: 12.2%, 11.8%, and 3.0%; MMR II: 11.7%, 11.5%, and 5.2%, respectively). The dose of MMR-RIT induced robust immune responses that were not inferior to those of MMR II, and was well tolerated.
Collapse
|
29
|
Barateau A, Perichon N, Hervé C, Henry O, Castelli J, Chajon E, De Crevoisier R, Lafond C. PO-0962: CBCT dose calculation in head and neck adaptive radiotherapy: accuracy assessment of four methods. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31272-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
30
|
Willame C, Henry O, Lin L, Vetter V, Baril L, Praet N. Pain caused by measles, mumps, and rubella vaccines: A systematic literature review. Vaccine 2018; 35:5551-5558. [PMID: 28893478 DOI: 10.1016/j.vaccine.2017.08.068] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 08/04/2017] [Accepted: 08/24/2017] [Indexed: 11/19/2022]
Abstract
PURPOSE The risk of post-vaccination adverse events (AEs) is a primary public health concern. Among the AEs, pain is a significant source of anxiety for both children and their parents. This review describes and assesses the intensity of pain experienced by children post-vaccination with widely used Measles-Mumps-Rubella (MMR) vaccines. METHODS A systematic literature search was conducted in Pubmed, Embase and Cochrane to identify publications describing immediate pain at injection site (primary objective) or pain within days (secondary objective) after 2 specific MMR vaccines. Immediate pain ('acute pain' according to the Brighton Collaboration case definition) was defined as pain occurring at the time or within 5min of injection. RESULTS Four studies, which compared the intensity of immediate injection site pain experienced by children after MMR vaccination, were identified. Various pain assessment tools and methods were used to quantify the intensity of pain, including the median difference in Visual Analog Scale scores between vaccine groups. All four studies showed significantly less immediate pain caused by Priorix (GSK Vaccines) compared with M-M-R II (Merck & Co., Inc.). CONCLUSIONS To our knowledge, this review summarizes for the first time the available scientific evidence on the intensity of pain following different MMR vaccines. It highlights that MMR vaccines can differ in terms of immediate pain. Further research may be needed to better understand the underlying reason for this observation. In this context, it is very important to understand which physicochemical properties are most relevant for the immediate pain profile of a vaccine to thereby support the development of vaccines with the best possible immediate pain profile.
Collapse
Affiliation(s)
- Corinne Willame
- Business & Decision Life Sciences, Rue Saint Lambert 141, 1200 Brussels, Belgium(1).
| | - Ouzama Henry
- GSK, 2301 Renaissance Blvd., King of Prussia, Philadelphia, PA 19406-2772, USA.
| | - Lan Lin
- GSK, Avenue Fleming 20, 1300 Wavre, Belgium.
| | | | | | | |
Collapse
|
31
|
Barateau A, Céleste M, Lafond C, Henry O, Couespel S, Simon A, Acosta O, de Crevoisier R, Périchon N. Calcul de dose de radiothérapie à partir de tomographies coniques : état de l’art. Cancer Radiother 2018; 22:85-100. [PMID: 29276135 DOI: 10.1016/j.canrad.2017.07.050] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Revised: 06/06/2017] [Accepted: 07/07/2017] [Indexed: 01/26/2023]
|
32
|
Henry O, Brzostek J, Czajka H, Leviniene G, Reshetko O, Gasparini R, Pazdiora P, Plesca D, Desole MG, Kevalas R, Gabutti G, Povey M, Innis B. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine 2017; 36:381-387. [PMID: 29224964 DOI: 10.1016/j.vaccine.2017.11.081] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 11/29/2017] [Accepted: 11/30/2017] [Indexed: 02/03/2023]
Abstract
BACKGROUND This phase III B follow-up of an initial multicenter study (NCT00226499) will evaluate the ten-year efficacy of two doses of the combined measles-mumps-rubella-varicella vaccine (MMRV) and one dose of the live attenuated varicella vaccine (V) versus a measles-mumps-rubella control group (MMR) for the prevention of clinical varicella disease. Here we present efficacy results for six years post-vaccination. METHODS In phase A of the study, healthy children aged 12-22 months from ten European countries were randomized (3:3:1) and received either two doses of MMRV, or one dose of combined MMR and one dose of monovalent varicella vaccine (MMR+V), or two doses of the MMR vaccine (control), 42 days apart. Vaccine efficacy against all and against moderate or severe varicella (confirmed by detection of viral DNA or epidemiological link) was assessed from six weeks up to six years post-dose 2 for the MMRV and MMR+V groups, and was calculated with 95% confidence intervals (CI). The severity of varicella was calculated using the modified Vázquez scale (mild ≤ 7; moderately severe = 8-15; severe ≥ 16). Herpes zoster cases were also recorded. RESULTS 5289 children (MMRV = 2279, mean age = 14.2, standard deviation [SD] = 2.5; MMR+V = 2266, mean age = 14.2, SD = 2.4; MMR = 744, mean age = 14.2, SD = 2.5 months) were included in the efficacy cohort. 815 varicella cases were confirmed. Efficacy of two doses of MMRV against all and against moderate or severe varicella was 95.0% (95% CI: 93.6-96.2) and 99.0% (95% CI: 97.7-99.6), respectively. Efficacy of one dose of varicella vaccine against all and against moderate or severe varicella was 67.0% (95% CI: 61.8-71.4) and 90.3% (95% CI: 86.9-92.8), respectively. There were four confirmed herpes zoster cases (MMR+V = 2, MMR = 2), all were mild and three tested positive for the wild-type virus. CONCLUSIONS Two doses of the MMRV vaccine and one dose of the varicella vaccine remain efficacious through six years post-vaccination.
Collapse
Affiliation(s)
- Ouzama Henry
- Vaccine Discovery and Development, GSK, Philadelphia, United States.
| | | | - Hanna Czajka
- Infectious Diseases Outpatient Clinic, The St. Luis Provincial Specialist Children's Hospital, Cracow, Poland.
| | - Giedra Leviniene
- Pediatric Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania.
| | - Olga Reshetko
- Pharmacology, Saratov Medical University, Saratov, Russia.
| | | | - Petr Pazdiora
- Department of Epidemiology, Medical Faculty Pilsen of Charles University, Czech Republic.
| | - Doina Plesca
- Pediatrics, University of Medicine and Pharmacy, Bucharest, Romania.
| | | | - Rimantas Kevalas
- Pediatric Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania.
| | - Giovanni Gabutti
- Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
| | | | - Bruce Innis
- Vaccine Discovery and Development, GSK, Philadelphia, United States.
| |
Collapse
|
33
|
Barateau A, Perichon N, Hervé C, Henry O, Crevoisier RD, Lafond C. 43. CBCT dose calculation: accuracy assessment of four different methods. Phys Med 2017. [DOI: 10.1016/j.ejmp.2017.10.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
34
|
Barateau A, Périchon N, Couespel S, Castelli J, Lafond C, Chajon E, Henry O, de Crevoisier R. Quantification de la dose cumulée délivrée aux parotides, avec ou sans replanification, à partir de tomographies coniques. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Barateau A, Perichon N, Couespel S, Castelli J, Lafond C, Chajon E, Henry O, de Crevoisier R. Peut-on calculer une distribution de dose à partir de tomographies coniques pour suivre la dose délivrée en cours de radiothérapie ORL ? Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
36
|
Castelli J, Simon A, Rigaud B, Lafond C, Henry O, Chajon E, Jégoux F, Vauleon E, de Crevoisier R. Radiothérapie adaptive des cancers ORL : bénéfice sur la couverture du volume tumoral. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Bellec J, Delaby N, Jouyaux F, Perdrieux M, Bouvier J, Sorel S, Henry O, Lafond C. Plan delivery quality assurance for CyberKnife: Statistical process control analysis of 350 film-based patient-specific QAs. Phys Med 2017; 39:50-58. [DOI: 10.1016/j.ejmp.2017.06.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 04/28/2017] [Accepted: 06/14/2017] [Indexed: 11/30/2022] Open
|
38
|
Berry AA, Abu-Elyazeed R, Diaz-Perez C, Mufson MA, Harrison CJ, Leonardi M, Twiggs JD, Peltier C, Grogg S, Carbayo A, Shapiro S, Povey M, Baccarini C, Innis BL, Henry O. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin. Hum Vaccin Immunother 2017; 13:1516-1522. [PMID: 28481690 PMCID: PMC5512763 DOI: 10.1080/21645515.2017.1309486] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12-15 months of age in the primary study (NCT00861744), were followed-up for 2 y post-vaccination. Anti-measles and anti-rubella antibodies were measured using Enzyme-Linked Immunosorbent Assay (ELISA), and anti-mumps antibodies using ELISA and plaque reduction neutralization (PRN) assays. Serious adverse events (SAEs) were recorded during the entire follow-up. The according-to-protocol (ATP) persistence cohort included 752 children (M-M-R II = 186, MMR-RIT = 566), who received primary vaccination at a mean age of 12.3 ( ± 0.67) months. 104 children were revaccinated with MMR-containing vaccines; therefore, serology results for timepoints after revaccination were excluded from the analysis. Seropositivity for measles (Year 1≥ 98.3%; Year 2≥ 99.4%) and rubella (Year 1≥ 98.9%; Year 2 = 100%) remained as high at Year 2 as at Day 42. Similarly, seropositivity for mumps determined by ELISA (Year 1≥ 90.1%; Year 2≥ 94.1%) and PRN assays (Year 1≥ 87.5%; Year 2≥ 91.7%) persisted. Thirty-three SAEs were recorded in 23 children; 2 SAEs (inguinal adenitis and idiopathic thrombocytopenic purpura) and one SAE (febrile convulsion) were considered as potentially related to MMR-RIT and M-M-R II, respectively. This study showed that antibodies against measles, mumps and rubella persisted for up to 2 y post-vaccination with either MMR vaccine in children aged 12-15 months, and that both vaccines were well-tolerated during the follow-up period.
Collapse
Affiliation(s)
- Andrea A Berry
- a Center for Vaccine Development , Institute for Global Health, University of Maryland School of Medicine , Baltimore , MD , USA
| | | | - Clemente Diaz-Perez
- c School of Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan PR , Puerto Rico
| | - Maurice A Mufson
- d Joan C. Edwards School of Medicine, Marshall University , Huntington , WV , USA
| | - Christopher J Harrison
- e Children's Mercy Hospital and Clinics, and University of Missouri at Kansas City , Kansas City , MO , USA
| | | | | | | | - Stanley Grogg
- i Oklahoma State University, Center for Health Sciences , Tulsa , OK , USA
| | - Antonio Carbayo
- j Full Health University Medical Clinic , Santa Ana , CA , USA
| | | | | | | | | | | |
Collapse
|
39
|
Perichon N, Couespel S, Hervé C, Henry O, Lafond C, Castelli J, Largent A, Acosta O, Chajon E, De Crevoisier R. EP-1490: A 3-class density method to monitor doses to the parotid glands and spinal cord in oropharynx IMRT. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31925-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
40
|
Martin S, Delaby N, Henry O, Chajon E, Lafond C. 34. Optimal treatment planning for head and neck VMAT: Evaluation of a tool to predict parotids sparing. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.11.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
41
|
Lafond C, A. Simon, Henry O, Perichon N, Castelli J, Acosta O, De Crevoisier R. 5. Adaptive radiotherapy: methods and tools. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.11.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
42
|
Henry O, Klein NP, Povey M, Parra MM, Diez-Domingo J, Ahonen A, Abu-Elyazeed R, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Innis BL, Carryn S. A Randomized, Consistency Study Comparing Immunogenicity and Safety of 2 Vaccines Against Measles, Mumps and Rubella (MMR) Administered to Children 12–15 Months of Age. Open Forum Infect Dis 2016. [DOI: 10.1093/ofid/ofw194.112] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | | | | | - Javier Diez-Domingo
- Vaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica, Valencia, Spain
| | | | | | | | | | | | - Gary S. Marshall
- University of Louisville School of Medicine, Louisville, Kentucky
| | | | | | | | - John A. Fling
- University of North Texas Health Science Centre, Fort Worth, Texas
| | | | - Maribel Campos
- Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico
| | - Iona Munjal
- Pediatric Infectious Disease, The Children's Hospital at Montefiore, Bronx, New York
| | | | - Timo Vesikari
- Vaccine Research Center, University of Tampere, Tampere, Finland
| | | | | | | |
Collapse
|
43
|
de Crevoisier R, Duvergé L, Hulot C, Chauvet B, Henry O, Bouvet C, Castelli J. [Interest of positioning control in onboard imaging and its delegation to the therapists]. Cancer Radiother 2016; 20:601-7. [PMID: 27614503 DOI: 10.1016/j.canrad.2016.07.084] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Accepted: 07/29/2016] [Indexed: 10/21/2022]
Abstract
The delegation of the on board imaging position control, from the radiation oncologist to the therapist, is justified by the generalization of the image-guided radiotherapy techniques which are particularly time consuming. This delegation is however partial. Indeed, the validation of the position by the therapist can be clearly performed when the registration is based on bony landmark or fiducial. The radiation oncologist needs however to make the validation in case of large target displacement, in more complex soft tissue-based registration, and in case of stereotactic body radiation therapy. Moreover, this delegation implies at least three conditions which are first the training of the staff, then the formalization of the procedures, responsibilities and delegations and finally, the evaluation of the practices of IGRT.
Collapse
Affiliation(s)
- R de Crevoisier
- Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France.
| | - L Duvergé
- Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France
| | - C Hulot
- Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France
| | - B Chauvet
- Département de radiothérapie, institut Sainte-Catherine, 84918 Avignon cedex 9, France
| | - O Henry
- Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France
| | - C Bouvet
- Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France
| | - J Castelli
- Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France
| |
Collapse
|
44
|
Durando P, Esposito S, Bona G, Cuccia M, Desole MG, Ferrera G, Gabutti G, Pellegrino A, Salvini F, Henry O, Povey M, Marchetti F. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy. Vaccine 2016; 34:4278-84. [DOI: 10.1016/j.vaccine.2016.07.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 06/23/2016] [Accepted: 07/07/2016] [Indexed: 10/21/2022]
|
45
|
Castelli J, Zhang P, Simon A, Rigaud B, Ospina Arango J, Nassef M, Lafond C, Henry O, Haigron P, Li B, Shu H, De crevoisier R. PO-0911: Optimal adaptive radiotherapy strategy in head and neck to spare the parotid glands. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32161-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Chesneau H, Lazaro D, Plagnard J, Lafond C, Henry O, Blideanu V. EP-1614: Comprehensive validation of a Monte Carlo kV-CBCT model using OSL and spectral measurements. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32865-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Lafond C, Simon A, Henry O, Périchon N, Castelli J, Acosta O, de Crevoisier R. Radiothérapie adaptative en routine ? État de l’art : point de vue du physicien médical. Cancer Radiother 2015; 19:450-7. [DOI: 10.1016/j.canrad.2015.06.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 06/01/2015] [Indexed: 12/22/2022]
|
48
|
Castelli J, Simon A, Henry O, Rigaud B, Chajon E, Ospina J, Lafond C, Laguerre B, Bénézéry K, de Crevoisier R. Nomogramme pour prédire le surdosage parotidien au cours de la radiothérapie conformationnelle avec modulation d’intensité des cancers ORL. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.07.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial. BMJ Open 2015; 5:e007202. [PMID: 26362659 PMCID: PMC4567664 DOI: 10.1136/bmjopen-2014-007202] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
OBJECTIVE This study (NCT00969436) compared the immunogenicity and safety of measles-mumps-rubella (MMR) followed by MMR+varicella (V) vaccines to (1) 2 doses of combined MMRV and (2) MMR followed by MMRV, in Indian children. DESIGN Phase III, open, randomised, non-inferiority study. SETTING 6 tertiary care hospitals located in India. PARTICIPANTS Healthy participants aged 9-10 months not previously vaccinated against/exposed to measles, mumps, rubella and varicella or without a history of these diseases. INTERVENTIONS Participants were randomised (2:2:1) to receive 2 doses of either MMRV (MMRV/MMRV group) or MMR followed by MMRV (MMR/MMRV group) or MMR followed by MMR+V (MMR/MMR+V, control group) at 9 and 15 months of age. Antibody titres against measles, mumps and rubella were measured using ELISA and against varicella using an immunofluorescence assay. MAIN OUTCOME MEASURES To demonstrate non-inferiority of the 2 vaccination regimens versus the control in terms of seroconversion rates, defined as a group difference with a lower bound of the 95% CI >-10% for each antigen, 43 days postdose 2. Parents/guardians recorded solicited local and general symptoms for a 4-day and 43-day period after each vaccine dose, respectively. RESULTS Seroconversion rates postdose 1 ranged from 87.5% to 93.2% for measles, 83.3% to 86.1% for mumps and 98.7% to 100% for rubella across the 3 vaccine groups. The seroconversion rates postdose 2 were 100% for measles, mumps and rubella and at least 95.8% for varicella across the 3 vaccine groups. Non-inferiority of MMRV/MMRV and MMR/MMRV to MMR/MMR+V was achieved for all antigens, 43 days postdose 2. The 3 vaccination regimens were generally well tolerated in terms of solicited local and general symptoms. CONCLUSIONS The immune responses elicited by the MMRV/MMRV and MMR/MMRV vaccination regimens were non-inferior to those elicited by the MMR/MMR+V regimen for all antigens. The 3 vaccination schedules also exhibited an acceptable safety profile in Indian children. TRIAL REGISTRATION NUMBER NCT00969436.
Collapse
Affiliation(s)
- Sanjay Lalwani
- Department of Pediatrics, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India
| | - Sukanta Chatterjee
- Department of Pediatrics, Medical College Kolkata, Kolkata, West Bengal, India
| | | | - Ashish Bavdekar
- Department of Pediatrics, KEM Hospital, Pune, Maharashtra, India
| | | | | | | | - Ouzama Henry
- GSK Vaccines, King of Prussia, Philadelphia, USA
| |
Collapse
|
50
|
Colliaux J, Castelli J, Chajon E, Bellec J, Henry O, Le Prisé E, Léna H, Corre R, De Crevoisier R. EP-1168 Tumor regression on CBCT predicts the risk of recurrence and death in locally advanced non-small cell lung cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41160-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|